Oncopia Therapeutics disclosed new patent-protected PROTAC designs targeting PRMT5, a protein arginine N-methyltransferase implicated in cancer biology. The platform pairs an E3 ubiquitin ligase-binding moiety with a PRMT5-targeting component, aiming to drive targeted protein degradation for future oncology programs.